David Mutimer

Medicine & Life Sciences

1. Liver Transplantation 100%
2. Hepacivirus 82%
3. Chronic Hepatitis B 48%
4. Hepatitis C 43%
5. Antiviral Agents 41%
6. Chronic Hepatitis C 40%
7. Hepatitis B virus 38%
8. Virus Diseases 38%
9. Fibrosis 38%
10. Lamivudine 37%
11. Ribavirin 35%
12. Hepatitis B 34%
13. Interferons 31%
14. Acute Liver Failure 31%
15. Infections 28%
16. Genotype 27%
17. Transplantation 25%
18. Liver 25%
19. Transplants 23%
20. Tissue Donors 23%
21. entecavir 22%
22. Therapeutics 21%
23. Liver Diseases 21%
24. adefovir 14%
25. Transplant Recipients 14%
26. telaprevir 13%
27. Hepatitis 13%
28. End Stage Liver Disease 12%
29. Recurrence 12%
30. adefovir dipivoxil 11%
31. Hepatitis B Surface Antigens 11%
32. Hepatitis B e Antigens 11%
33. Tacrolimus 11%
34. Guidelines 10%
35. Immunoglobulins 10%
36. Protease Inhibitors 10%
37. Mortality 9%
38. DNA 9%
39. Cyclosporine 9%
40. Serum 8%
41. Hepatocellular Carcinoma 8%
42. ITX-5061 8%
43. Acetaminophen 8%
44. N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 7%
45. Viruses 7%
46. Liver Failure 7%
47. Cytomegalovirus 7%
48. alisporivir 7%
49. glecaprevir and pibrentasvir 6%
50. Sofosbuvir 6%